Abstract: A method for preparing an antibody-drug conjugate. The antibody-drug conjugate is formed by means of site-directed conjugation on the basis of an N-glycosylation site of an Fc region of an antibody. The method comprises: (1) providing a donor containing an oxazoline oligosaccharide, an antibody containing a GlcNAc motif, and an immobilized endoglycosidase having a glycoside transfer activity; and (2) covalently linking the activated donor containing the oxazoline oligosaccharide to the antibody containing the GlcNAc motif by means of the catalytic action of the endoglycosidase; therefore, one-step conjugation is realized. The present invention also relates to an endoglycosidase fusion protein, which comprises a covalently linked endoglycosidase, a Halo tag, and/or a His tag.

Abstract: An image processing method includes segmenting, by a cloud server and based on a zoom ratio of a high-definition image in a high-definition image library, a low-definition image of a small zoom ratio from a terminal to obtain a plurality of image blocks. For each image block, performing, by the cloud server, retrieval and matching in the high-definition image library to obtain one or more high-definition reference images, and then performing, by the cloud server, image quality improvement using an image enhancement network that is based on the high-definition reference images to obtain a plurality of high-definition image blocks. Finally, stitching, by the cloud server, the high-definition image blocks into a super-definition image with higher resolution and higher definition, and returning, by the cloud server, the super-definition image to the terminal.

Abstract: Aspects relate to techniques for efficient sidelink resource reservation based on the congestion on a sidelink. A wireless communication device may transmit control information indicating a number of resources reserved for an initial transmission and at least one retransmission of a packet. In some examples, the number of resources included in the control information can be either three resources or two resources based on the congestion. For example, the number of resources included in the control information can be three resources in response to a congestion value representing the congestion on the sidelink being less than a threshold. In addition, the number of resources included in the control information can be two resources in response to the congestion value being greater than or equal to the threshold.

Abstract: The embodiments of the present disclosure provide a display substrate, a display panel, and a display device. The display substrate includes: a first base substrate, wherein a plurality of sub-pixel regions arranged in an array are provided on the first base substrate; and a reflective layer provided on one side of the first base substrate, wherein a surface of the reflective layer away from the first base substrate is formed to include a plurality of first bumps and a plurality of second bumps, and the first bump has a size greater than that of the second bump.

Abstract: Provided are a liquid crystal antenna and a manufacturing method thereof. The liquid crystal antenna includes a first substrate, a second substrate and a third substrate that are stacked. The first substrate and the second substrate constitute a first box-shaped structure. A first space is disposed between the first substrate and the second substrate. The first space is filled with a liquid crystal layer. The second substrate and the third substrate constitute a second box-shaped structure. A second conductive pattern layer is disposed on a side of the second substrate. A third conductive pattern layer is disposed on a single side of the third substrate. A second space is disposed between the second substrate and the third substrate.

Abstract: A conjugation device includes at least one flow reactor having an inlet and an outlet, the flow reactor(s) being completely filled with a support such as a matrix including 1) chromatography beads, fibers or membranes, and 2) a biologic catalyzer, namely the enzyme ligase, which is immobilized onto this support; a fluid delivery unit in fluid communication with the inlet of the flow reactor(s) and configured to continuously provide the flow reactor(s) with at least one kind of reaction fluid such as antibody and linker-payload according to stages of the conjugation process, the at least one kind of process fluid including a first moiety and a second moiety of a conjugate to be produced; and a fluid collection unit in fluid communication with the outlet of the flow reactor(s) and configured to control collection of fluid flowing out of the outlet of the flow reactor(s) according to the stages of the conjugation process.

Abstract: A conjugation device includes at least one flow reactor having an inlet and an outlet, the flow reactor(s) being completely filled with a support such as a matrix including 1) chromatography beads, fibers or membranes, and 2) a biologic catalyzer, namely the enzyme ligase, which is immobilized onto this support; a fluid delivery unit in fluid communication with the inlet of the flow reactor(s) and configured to continuously provide the flow reactor(s) with at least one kind of reaction fluid such as antibody and linker-payload according to stages of the conjugation process, the at least one kind of process fluid including a first moiety and a second moiety of a conjugate to be produced; and a fluid collection unit in fluid communication with the outlet of the flow reactor(s) and configured to control collection of fluid flowing out of the outlet of the flow reactor(s) according to the stages of the conjugation process.

Abstract: The disclosure relates to a linking unit molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof, and in particular relates to an anti-HER2 antibody-immune agonist conjugate (AIAC) as a novel type of cancer therapy.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

Abstract: The present disclosure further relates to a linker-payload compound including an oligosaccharide group, especially a disaccharide group, where the oligosaccharide group is linked to the remainder of the compound by an amide bond. The present disclosure further relates to an antibody-drug conjugate (ADC) containing the linker-payload compound, where the glycan chain in an antibody is remodeled with the oligosaccharide moiety in the linker-payload compound. The present disclosure further relates to preparation methods and use of the above-mentioned substances.

Abstract: The present disclosure relates to a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.

Abstract: The present invention provides a conjugate and preparation method thereof, a pharmaceutical composition comprising the conjugate and use of the pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of a disease.

Abstract: A conjugate and preparation method therefor, comprising a medication composition comprising the conjugate and a use of the medication composition in preparing medications for the treatment or prevention of diseases.

Abstract: A wiring design method and a wiring structure for a package substrate in a flip chip, and a flip chip. The wiring design method includes: arranging bump pads in an array of rows and columns, wherein the bump pads are configured to bond with conductive bumps on a flip chip die, and the bump pads comprise signal pads and non-signal pads; providing the non-signal pad with a via hole; and using a layer of wiring to lead a subset of the signal pads out of an orthographic projection region of the flip chip die on the package substrate, wherein the subset of the signal pads is configured to carry all functional signals required by design specifications of the flip chip die for the array of the bump pads.

Abstract: The present disclosure relates to the biopharmaceutical field, in particular, Exatecan derivatives, linker-payloads, and conjugates and thereof antibody-drug conjugates, and the corresponding preparing process and use thereof.

Abstract: The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

Abstract: The present disclosure relates to a linker molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof.

Abstract: The present disclosure relates to a linking unit molecule for targeting molecule-drug conjugate, and the corresponding conjugate, the preparation and use thereof, and in particular relates to an antibody-immune agonist conjugate (AIAC) as a novel type of cancer therapy.